Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.
Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A, Jones I, Arm JP, Strieter RM, Sabo R, Gunawardena KA. Rothenberg ME, et al. Among authors: jones i. J Allergy Clin Immunol. 2015 Feb;135(2):500-7. doi: 10.1016/j.jaci.2014.07.049. Epub 2014 Sep 13. J Allergy Clin Immunol. 2015. PMID: 25226850 Clinical Trial.
Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM, Shamji MH, Dumitru FA, Calderon MA, Scadding GW, Makatsori M, Jones I, He QA, Subramanian KK, Arm JP, Durham SR, Schmidt-Weber CB. Chaker AM, et al. Among authors: jones i. J Allergy Clin Immunol. 2016 Feb;137(2):452-461.e9. doi: 10.1016/j.jaci.2015.08.046. Epub 2015 Oct 31. J Allergy Clin Immunol. 2016. PMID: 26531865 Clinical Trial.
Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).
Kazani S, Rowlands DJ, Bottoli I, Milojevic J, Alcantara J, Jones I, Kulmatycki K, Machineni S, Mostovy L, Nicholls I, Nick JA, Rowe SM, Simmonds NJ, Vegesna R, Verheijen J, Danahay H, Gosling M, Ayalavajjala PS, Salman M, Strieter R. Kazani S, et al. Among authors: jones i. J Cyst Fibros. 2021 Mar;20(2):250-256. doi: 10.1016/j.jcf.2020.11.002. Epub 2020 Dec 6. J Cyst Fibros. 2021. PMID: 33293212 Free PMC article.
Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial.
Rowe SM, Jones I, Dransfield MT, Haque N, Gleason S, Hayes KA, Kulmatycki K, Yates DP, Danahay H, Gosling M, Rowlands DJ, Grant SS. Rowe SM, et al. Among authors: jones i. Int J Chron Obstruct Pulmon Dis. 2020 Oct 5;15:2399-2409. doi: 10.2147/COPD.S257474. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 33116455 Free PMC article. Clinical Trial.
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
Singh D, Wild JM, Saralaya D, Lawson R, Marshall H, Goldin J, Brown MS, Kostikas K, Belmore K, Fogel R, Patalano F, Drollmann A, Machineni S, Jones I, Yates D, Tillmann HC. Singh D, et al. Among authors: jones i. Respir Res. 2022 Feb 10;23(1):26. doi: 10.1186/s12931-022-01949-3. Respir Res. 2022. PMID: 35144620 Free PMC article. Clinical Trial.
Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
Watz H, Hohlfeld JM, Singh D, Beier J, Diamant Z, Liu J, Hua S, Abd-Elaziz K, Pinot P, Jones I, Tillmann HC. Watz H, et al. Among authors: jones i. Respir Res. 2020 Apr 15;21(1):87. doi: 10.1186/s12931-020-01349-5. Respir Res. 2020. PMID: 32295593 Free PMC article. Clinical Trial.
2,148 results